Analyst Price Target is $26.40
▲ +51.29% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Werewolf Therapeutics in the last 3 months. The average price target is $26.40, with a high forecast of $32.00 and a low forecast of $22.00. The average price target represents a 51.29% upside from the last price of $17.45.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Werewolf Therapeutics.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.